Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,942.71 -611.75 (-0.95%) CMC Crypto 200
1,329.52 -67.02 (-4.80%)
Dr. Reddy's Laboratories Limited (RDY)
After hours:
| Previous close | 74.02 |
| Open | 74.27 |
| Bid | 74.57 x 800 |
| Ask | 74.60 x 1100 |
| Day's range | 74.26 - 74.78 |
| 52-week range | 53.12 - 77.72 |
| Volume | |
| Avg. volume | 196,456 |
| Market cap | 12.512B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.83 |
| EPS (TTM) | 3.76 |
| Earnings date | N/A |
| Forward dividend & yield | 0.49 (0.66%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | 79.79 |
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
